Protara Therapeutics, Inc. develops clinical-stage biotechnology programs for cancer and rare diseases. Company news centers on TARA-002, an investigational cell-based therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, including updates from the ADVANCED-2 trial in BCG-Unresponsive and BCG-Naïve NMIBC patient groups.
Recurring updates also cover IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving long-term parenteral support. Other company announcements include clinical-conference presentations, FDA designation updates, financial results, equity compensation grants under Nasdaq rules, and capital-raising activity tied to Protara's development-stage pipeline.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced plans to present a Trials in Progress poster on TARA-002 at the American Society of Clinical Oncology Annual Meeting from June 3-7, 2022. The ADVANCED-1 Phase 1 trial aims to evaluate TARA-002, an investigational immunopotentiator for non-muscle invasive bladder cancer (NMIBC). The trial is designed to assess the safety and preliminary anti-tumor activity of TARA-002 in treatment-naïve and experienced patients. Approximately 65,000 NMIBC cases are diagnosed annually in the U.S., emphasizing the need for new treatment options.
Protara Therapeutics, Inc. (Nasdaq: TARA) has announced its participation in the H.C. Wainwright Global Investment Conference from May 23 to May 26, 2022. Their prerecorded presentation will be available on May 24, 2022, at 7:00 a.m. ET. Interested viewers can access it via the Events and Presentations section of Protara's website, where it will be archived for 90 days. Protara focuses on developing therapies for cancer and rare diseases, including TARA-002 for bladder cancer and IV Choline Chloride for intestinal failure-related liver disease.
Protara Therapeutics (Nasdaq: TARA) announced positive results from a retrospective analysis of OK-432, the basis for its investigational therapy TARA-002, targeting lymphatic malformations (LMs). Presented at the ISSVA World Congress 2022, the analysis involved 246 patients, showing approximately 69% clinical success in immediate treatment groups versus 7.5% in delayed groups. Serious adverse events were rare, with a favorable safety profile noted. These findings bolster the potential for TARA-002 to provide a much-needed FDA-approved treatment for LMs.
Protara Therapeutics (Nasdaq: TARA) announced dosing has begun in the Phase 1 ADVANCED-1 study of TARA-002 for non-muscle invasive bladder cancer (NMIBC). The company reported cash and investments of $119 million as of March 31, 2022, allowing funding through mid-2024. The Phase 2 trial for TARA-002 in lymphatic malformations is also planned following guidance from the FDA. Financially, R&D expenses decreased to $5.3 million from $7.0 million year-over-year, while the net loss narrowed to $10.8 million, or $0.96 per share.
Protara Therapeutics (Nasdaq: TARA) announced the dosing of the first patient in its Phase 1 clinical trial, ADVANCED-1, investigating TARA-002 for non-muscle invasive bladder cancer (NMIBC). This trial targets treatment-naïve and experienced patients with high-grade tumors. The primary goal is to evaluate TARA-002's safety and anti-tumor activity, setting the stage for a potential Phase 2 study. NMIBC accounts for 80% of bladder cancer cases, with a pressing need for effective treatment options.
Protara Therapeutics (TARA) has commenced a Phase 1 clinical trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC), following FDA IND clearance in October 2021. The company reported a strong cash position of $130.7M as of December 31, 2021, expected to fund operations into mid-2024. Research and development expenses rose to $21.1M for 2021, up from $12.0M the previous year. Protara registered a net loss of $10.2M in Q4 2021, compared to $8.8M in Q4 2020, with total net losses of $47.3M for 2021.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in two virtual fireside chats at upcoming healthcare conferences. The Cowen 42nd Annual Health Care Conference is scheduled for March 9, 2022, at 9:10 am ET, followed by the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 2:00 pm ET. Interested parties can access the live webcasts on Protara's website, where they will remain archived for 90 days. Protara focuses on innovative therapies for cancer and rare diseases, including its lead program TARA-002.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced its participation in a virtual fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 9, 2022, at 4:00 PM ET. Interested parties can access the live webcast through the Events and Presentations section of the Company’s website, which will remain archived for 90 days post-event. Protara focuses on developing transformative therapies for cancer and rare diseases, including its lead program, TARA-002, aimed at treating non-muscle invasive bladder cancer and lymphatic malformations.
Protara Therapeutics (Nasdaq: TARA) has appointed Dr. Jathin Bandari as Chief Medical Officer. He previously served as the Vice President of Clinical Development and was Interim CMO. Dr. Bandari, a urologic oncologist with extensive experience, will lead the development of TARA-002, a therapy for non-muscle invasive bladder cancer. Under his leadership, Protara aims to advance its oncology portfolio and explore new applications for TARA-002. Dr. Bandari is a respected figure in oncology with a significant number of publications and contributions to the field.
Protara Therapeutics, Inc. (Nasdaq: TARA) will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation will be available on January 10 at 7:00 am ET through the Company's website. Protara focuses on developing therapies for cancer and rare diseases, featuring its lead program TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations. Additionally, IV Choline Chloride targets intestinal failure-associated liver disease. The presentation will be archived for 90 days on their website.